<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2176-6223</journal-id>
<journal-title><![CDATA[Revista Pan-Amazônica de Saúde]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Pan-Amaz Saude]]></abbrev-journal-title>
<issn>2176-6223</issn>
<publisher>
<publisher-name><![CDATA[Instituto Evandro Chagas. Secretaria de Vigilância em Saúde e Ambiente. Ministério da Saúde]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2176-62232014000300019</article-id>
<article-id pub-id-type="doi">10.5123/s2176-62232014000300003</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Recidiva hansênica em área de alta endemicidade no Estado do Pará, Brasil]]></article-title>
<article-title xml:lang="en"><![CDATA[Recurrence of leprosy cases in a highly endemic area in Pará State, Brazil]]></article-title>
<article-title xml:lang="es"><![CDATA[Recidiva hansénica en área de alta endemicidad en el Estado de Pará, Brasil]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[Suenny Leal]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Macedo]]></surname>
<given-names><![CDATA[Geraldo Mariano Moraes de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pires]]></surname>
<given-names><![CDATA[Carla Andrea Avelar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[Maria Heliana Chaves Monteiro da]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Escola Superior Madre Celeste  ]]></institution>
<addr-line><![CDATA[Ananindeua Pará]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Federal do Pará Núcleo de Medicina Tropical ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2014</year>
</pub-date>
<volume>5</volume>
<numero>3</numero>
<fpage>19</fpage>
<lpage>24</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S2176-62232014000300019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S2176-62232014000300019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S2176-62232014000300019&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO Considera-se como um caso de recidiva hansênica, o indivíduo que, após ter recebido alta por cura, apresente sinais clínicos de atividade da doença. Com o objetivo de conhecer a ocorrência de casos de recidiva e fatores clínico-epidemiológicos relacionados, em pacientes em uma região hiperendêmica, foi realizada uma pesquisa cujos métodos abrangem um estudo epidemiológico, transversal com caráter descritivo entre janeiro de 2007 e dezembro de 2008, com dados fornecidos pela Unidade de Referência Especializada (URE) em hanseníase Dr. Marcello Candia, no Estado do Pará, Brasil. Os resultados do estudo revelaram que dos 27 pacientes, 96,3% pertenciam à classificação multibacilar, predominantemente do sexo masculino (74,1%), com a faixa etária de 29 a 42 anos de idade (44,4%), a maioria da região metropolitana de Belém (70,4%). A manifestação clínica caracterizou-se por lesões novas (81,5%), com tempo de aparecimento entre cinco a dez anos (55,6%). O diagnóstico usou avaliação clínica e de índice baciloscópico (63%), destes 40,7% obtiveram baciloscopia entre 4 a 6 +. O grau de incapacidade em 44,4% não foi registrado no início do tratamento. Os casos de recidiva hansênica diagnosticados e tratados na URE Dr. Marcello Candia, em sua grande maioria, obedeceram aos critérios estabelecidos pelo Ministério da Saúde. O grau de incapacidade em alguns pacientes não apresentou resultado nessa avaliação, o qual é muito importante para a prevenção de incapacidades. A avaliação dermatoneurológica simplificada, preconizada pelo Ministério da Saúde, deve ser reforçada em sua importância em todos os serviços que atendem pacientes com hanseníase, visto que é essencial no diagnóstico precoce de danos neurológicos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT It is considered as a case of leprosy relapse, the individual who, after having been discharged for healing, has presented clinical signs of disease activity. In order to know the occurrence of relapse, clinical and epidemiological factors in patients in a hyperendemic region, a survey was conducted which methods comprise an epidemiological cross-sectional descriptive study from January 2007 to December 2008, with data provided by Specialized Reference Center (Unidade de Referência Especializada - URE) in leprosy Dr. Marcello Candia, in Pará State, Brazil. The results of the study revealed that 96.3% of 27 patients belonged to the multibacillary classification, predominantly male (74.1%), with the age group from 29 to 42 years old (44.4%), most came from Belém metropolitan region (70.4%). The clinical manifestation characterized by new lesions (81.5%), with time of appearance between five and ten years (55.6%). The diagnosis used clinical and bacteriological index assessment (63%), of these 40.7% were smear between 4-6 +. The degree of disability in 44.4% was not recorded at the beginning of treatment. The cases of leprosy diagnosed and treated at URE Dr. Marcello Candia, mostly, met the criteria established by Brazilian Ministry of Health. The degree of disability of some patients did not show the result in this evaluation, which it is very important to prevent disabilities. The simplified dermatological assessment recommended by Ministry of Health should be reinforced in its importance in all services that have leprosy patients, since it is essential for the early diagnosis of neurological damage.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Se considera un caso de recidiva hansénica, al individuo que, después de haber recibido alta por cura, presente señales clínicas de actividad de la enfermedad. Con el objetivo de conocer la ocurrencia de casos de recidiva y factores clínico-epidemiológicos relacionados, en pacientes en una región hiperendémica, se realizó una investigación cuyos métodos abarcan un estudio epidemiológico, transversal de carácter descriptivo entre enero de 2007 y diciembre de 2008, con datos suministrados por la Unidad de Referencia Especializada (URE) en hanseníasis Dr. Marcello Candia, en el Estado de Pará, Brasil. Los resultados del estudio revelaron que de los 27 pacientes, 96,3% pertenecían a la clasificación multibacilar, predominantemente del sexo masculino (74,1%), con una franja etaria de 29 a 42 años (44,4%), la mayoría de la región metropolitana de Belém (70,4%). La manifestación clínica se caracterizó por nuevas lesiones (81,5%), con un tiempo de aparecimiento entre cinco a diez años (55,6%). El diagnóstico usó evaluación clínica y de índice baciloscópico (IB) (63%), de estos un 40,7% obtuvo baciloscopia entre 4 a 6 +. El grado de incapacidad en 44,4% no fue registrado al inicio del tratamiento. Los casos de recidiva hansénica diagnosticados y tratados en la URE Dr. Marcello Candia, en su gran mayoría, obedecieron a los criterios establecidos por el Ministerio de Salud. El grado de incapacidad en algunos pacientes no arrojó resultados en esa evaluación, lo que es muy importante para la prevención de incapacidades. La evaluación dermatoneurológica simplificada, preconizada por el Ministerio de Salud, debe ser reforzada en su importancia en todos los servicios que atienden a pacientes con hanseníasis, visto que es esencial en el diagnóstico precoz de daños neurológicos.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Hanseníase]]></kwd>
<kwd lng="pt"><![CDATA[Recidiva]]></kwd>
<kwd lng="pt"><![CDATA[Terapêutica.]]></kwd>
<kwd lng="en"><![CDATA[Leprosy]]></kwd>
<kwd lng="en"><![CDATA[Recurrence]]></kwd>
<kwd lng="en"><![CDATA[Therapeutics.]]></kwd>
<kwd lng="es"><![CDATA[Lepra]]></kwd>
<kwd lng="es"><![CDATA[Recurrencia]]></kwd>
<kwd lng="es"><![CDATA[Terapéutica.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hanseníase: formas clínicas e diagnóstico diferencial]]></article-title>
<source><![CDATA[Medicina]]></source>
<year>1997</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>325-34</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Governo do Estado do Ceará</collab>
<source><![CDATA[Informe epidemiológico da hanseníase]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lastória]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[MAMM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hanseníase: diagnóstico e tratamento]]></article-title>
<source><![CDATA[Dermatologia]]></source>
<year>2012</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>173-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Krahenbuhl]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leprosy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>353</volume>
<numero>9153</numero>
<issue>9153</issue>
<page-range>655-60</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jamet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Baohong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen]]></article-title>
<collab>Marchoux Chemotherapy Study Group</collab>
<source><![CDATA[Int J Lepr Other Mycobact Dis]]></source>
<year>1995</year>
<volume>63</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>195-201</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jamet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relapses rate in multibacillary leprosy patients after stopping treatment with Rifampin - containing combines regimes]]></article-title>
<collab>Marchoux Chemotherapy Study Group</collab>
<source><![CDATA[Int J Lepr Other Mycobact Dis]]></source>
<year>1992</year>
<volume>60</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>525-35</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaimal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thappa]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relapse in leprosy]]></article-title>
<source><![CDATA[Indian J Dermatol Venereol Leprol]]></source>
<year>2009</year>
<volume>75</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>126-35</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[MFM]]></given-names>
</name>
</person-group>
<source><![CDATA[O retratamento em hanseníase: identificação dos fatores de risco, um estudo caso-controle]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Recife, PE ]]></publisher-loc>
<publisher-name><![CDATA[Universidade Federal de Pernambuco]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>Secretaria de Estado da Saúde de São Paulo. Coordenadoria de Controle de Doenças. Instituto Lauro de Souza Lima</collab>
<article-title xml:lang=""><![CDATA[Recidiva e resistência em hanseníase]]></article-title>
<source><![CDATA[Rev Saude Publica]]></source>
<year>2011</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>631-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features and diagnosis of relapses in leprosy]]></article-title>
<source><![CDATA[Indian J Lepr]]></source>
<year>1995</year>
<volume>67</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-59</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desikan]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relapse, reactivation or reinfection?]]></article-title>
<source><![CDATA[Indian J Lepr]]></source>
<year>1995</year>
<volume>67</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-11</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde. Gabinete do Ministro</collab>
<article-title xml:lang=""><![CDATA[Portaria n° 3.125, de 7 de outubro de 2010. Aprova as diretrizes para vigilância, atenção e controle da hanseníase]]></article-title>
<source><![CDATA[Diário Oficial da União]]></source>
<year>2010</year>
<page-range>55-60</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR)</collab>
<source><![CDATA[Vigilância em saúde: situação epidemiológica da hanseníase no Brasil]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ximenes]]></surname>
<given-names><![CDATA[RAA]]></given-names>
</name>
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[MEN]]></given-names>
</name>
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[MFM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retreatment in leprosy: a case-control study]]></article-title>
<source><![CDATA[Rev Saude Publica]]></source>
<year>2007</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>632-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gebre]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saunderson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Byass]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relapses after fixed duration multiple drug therapy: the AMFES cohort]]></article-title>
<source><![CDATA[Lepr Rev]]></source>
<year>2000</year>
<volume>71</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>325-31</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diniz]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Puppin]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[MLWDR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudo retrospectivo de recidiva da hanseníase no Estado do Espírito Santo]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop]]></source>
<year>2009</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>420-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pandian]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Sitambaram]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bharati]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ramu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relapses in non-lepromatous and intermediate forms of leprosy]]></article-title>
<source><![CDATA[Indian J Lepr]]></source>
<year>1983</year>
<volume>57</volume>
<page-range>149-58</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gelber]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Balagon]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Cellona]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low]]></article-title>
<source><![CDATA[Int J Lepr]]></source>
<year>2004</year>
<volume>72</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>493-500</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Diniz]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Salgado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aires]]></surname>
<given-names><![CDATA[MAP]]></given-names>
</name>
<name>
<surname><![CDATA[Nery]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>2012</year>
<volume>50</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1912-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Report of the workshop on sentinel surveillance for drug resistance in leprosy]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR)</collab>
<source><![CDATA[Guia de vigilância epidemiológica]]></source>
<year>2005</year>
<edition>6. ed</edition>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
